Checchi Capital Advisers LLC Has $730,000 Position in AstraZeneca plc (AZN)

Checchi Capital Advisers LLC boosted its holdings in AstraZeneca plc (NYSE:AZN) by 12.5% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 18,059 shares of the company’s stock after acquiring an additional 2,008 shares during the quarter. Checchi Capital Advisers LLC’s holdings in AstraZeneca were worth $730,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in AZN. Berman Capital Advisors LLC bought a new stake in shares of AstraZeneca during the fourth quarter worth $38,000. Pinnacle Bank bought a new stake in shares of AstraZeneca during the fourth quarter worth $38,000. Portfolio Solutions LLC bought a new stake in shares of AstraZeneca during the fourth quarter worth $40,000. Sontag Advisory LLC bought a new stake in shares of AstraZeneca during the fourth quarter worth $40,000. Finally, CNB Bank increased its position in shares of AstraZeneca by 245.0% during the fourth quarter. CNB Bank now owns 1,080 shares of the company’s stock worth $41,000 after acquiring an additional 767 shares in the last quarter. Institutional investors and hedge funds own 18.65% of the company’s stock.

Several equities research analysts have recently issued reports on AZN shares. Zacks Investment Research downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, February 5th. They set an “outperform” rating for the company. Exane BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, February 5th. They set an “outperform” rating for the company. ValuEngine raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Finally, Goldman Sachs Group reissued a “sell” rating on shares of AstraZeneca in a research report on Tuesday, February 26th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the stock. AstraZeneca presently has a consensus rating of “Hold” and an average target price of $45.29.

Shares of AZN opened at $38.61 on Thursday. AstraZeneca plc has a 12 month low of $34.38 and a 12 month high of $43.29. The firm has a market cap of $95.95 billion, a P/E ratio of 11.16, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a quick ratio of 0.58, a current ratio of 0.75 and a debt-to-equity ratio of 1.48.

AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, April 26th. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.02. AstraZeneca had a net margin of 10.75% and a return on equity of 37.91%. The business had revenue of $5.47 billion during the quarter, compared to analysts’ expectations of $5.40 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The firm’s revenue was up 9.6% on a year-over-year basis. As a group, equities research analysts predict that AstraZeneca plc will post 1.79 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Checchi Capital Advisers LLC Has $730,000 Position in AstraZeneca plc (AZN)” was first reported by WKRB News and is owned by of WKRB News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.wkrb13.com/2019/05/23/checchi-capital-advisers-llc-has-730000-position-in-astrazeneca-plc-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Stock Symbols, CUSIP and Other Stock Identifiers

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.